Compare CISO & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CISO | XCUR |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 13.7M |
| IPO Year | 2021 | 2017 |
| Metric | CISO | XCUR |
|---|---|---|
| Price | $0.26 | $1.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 443.0K | 43.1K |
| Earning Date | 05-15-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 79.31 | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.21 | $1.43 |
| 52 Week High | $1.48 | $9.50 |
| Indicator | CISO | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 31.68 |
| Support Level | $0.22 | N/A |
| Resistance Level | $0.32 | $3.40 |
| Average True Range (ATR) | 0.02 | 0.27 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 18.94 | 17.77 |
CISO Global Inc provides cybersecurity compliance and is a software firm composed of trained and seasoned security professionals. The services are used to protect clients' data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in the U.S., Chile, and all other countries. The maximum revenue is generated from the U.S. The products and services include: security managed services, professional services, and cybersecurity software.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.